Latest Recruitment News

EMVision Medical Devices reports strong progress in its emu™ Brain Scanner clinical trials, expanding recruitment across seven leading stroke hospitals and introducing new software features to enhance scan quality.

EDU Holdings Limited anticipates FY25 financial results near the top of its guidance, driven by strong revenue and profit growth from its higher education arm, Ikon Institute.

Anteris Technologies has completed a $90 million strategic investment from Medtronic as part of a $320 million capital raise, advancing its DurAVR transcatheter heart valve towards global commercialisation and pivotal clinical trials.

Anteris Technologies Global Corp. has entered a material definitive agreement to raise approximately $320 million through a public offering and a strategic private placement with Medtronic’s subsidiary. The capital will support clinical trials and manufacturing expansion for its innovative heart valve technology.

Nyrada Inc. has secured ethics approval to launch a Phase IIa clinical trial for its heart attack drug Xolatryp®, with patient recruitment set for March 2026. The company maintains a solid cash position of AU$7.12 million as it expands its research into oncology.

LTR Pharma has initiated dosing in its Phase II clinical trial for SPONTAN, a rapid-acting intranasal spray targeting erectile dysfunction, marking a key step toward FDA approval and commercial expansion.

Hiremii Limited has reported its highest-ever quarterly revenue and gross profit, driven by growth in its recruitment business and enhanced AI technology. The company also completed a significant capital raise to accelerate its expansion plans.

The Garvan Institute has won a $3 million MRFF grant to conduct pivotal pancreatic cancer studies, including one evaluating Syntara’s amsulostat combined with chemotherapy. Recruitment is slated to begin mid-2026 across major NSW cancer centres.

Noxopharm has successfully completed the final multiple-dose cohort of its HERACLES trial for SOF-SKN™, reporting no significant safety concerns and paving the way for Phase II-enabling studies.

Genetic Signatures reported a $3.3 million quarterly revenue with growing international sales and a robust cash position, while preparing for a leadership change.

Bellevue Gold Limited reported a strong December quarter with rising grades and record ore mined, alongside a strategic reduction in its hedge book ahead of schedule. The company also achieved net zero emissions at its flagship project, underscoring its operational and sustainability credentials.

Mesoblast has received encouraging feedback from the FDA on its cell therapy rexlemestrocel-L, showing meaningful pain relief and potential opioid use reduction in chronic low back pain patients. The company’s ongoing Phase 3 trial aims to confirm these benefits and advance regulatory approval.